Important Deadline Approaching for Shareholders of Altimmune, Inc. in Class Action Lawsuit

Important Class Action Notification for Altimmune, Inc. Shareholders

Shareholders of Altimmune, Inc. (NASDAQ: ALT) are urged to take action as a significant deadline approaches. The Gross Law Firm has announced a notice concerning a class action lawsuit that could affect shareholders who purchased shares of Altimmune within the defined class period from August 10, 2023, to June 25, 2025. The firm is actively seeking participants to take part in this class action, which aims to address allegations of misleading information and financial performance issues surrounding the company's stock.

On June 26, 2025, Altimmune released topline results from its IMPACT Phase 2b MASH trial concerning Pemvidutide, a drug intended for treating MASH (Metabolic Associated Steatotic Liver Disease). Unfortunately, the announcement revealed that the company failed to achieve statistical significance concerning its primary endpoint of fibrosis reduction. Prior to this release, the company had set inflated expectations about the trial outcomes, leading to disappointment among investors when the results did not reflect anticipated progress. The press release indicated that while there was a positive trend in fibrosis improvement, the results fell short of meeting statistical benchmarks due to an unexpectedly high placebo response.

The stock market reacted sharply to this news. Following the press release, shares of Altimmune plunged from a closing market price of $7.71 on June 25, 2025, to $3.61 the next day, representing a staggering 53.2% decrease in value within just 24 hours. Such dramatic declines often prompt concerns among shareholders, particularly those who may believe they were misled about the company’s prospects.

Deadline to Register
Shareholders looking to join the class action must register their information by October 6, 2025. This deadline is critical for those interested in the potential lead plaintiff appointment, although it is important to note that being appointed as a lead plaintiff is not a requirement for participating in the recovery efforts due to the lawsuit.

Once registered, shareholders will be included in a portfolio monitoring system that provides updates throughout the progression of the case. The Gross Law Firm emphasizes that there are no fees or obligations for shareholders to register and keep abreast of developments in the lawsuit.

Why Choose The Gross Law Firm?
The Gross Law Firm is a notable institution in the realm of securities class action litigation, renowned for advocating on behalf of investors who have faced losses due to fraudulent activities, misleading statements, or failure to disclose essential information. Their mission centers on holding companies accountable for unethical practices that result in financial harm to investors, thereby promoting responsible corporate behavior.

For shareholders of Altimmune who feel their rights may have been compromised during this period of misinformation and stock decline, reaching out to The Gross Law Firm is an essential next step. The firm is dedicated to protecting shareholders and ensuring accountability in the financial markets.

Shareholders can learn more and register for the class action lawsuit by visiting The Gross Law Firm's dedicated webpage here.

Contact Information:
For further inquiries, the Gross Law Firm can be contacted via the following: